BACKGROUND: Serum thyroglobulin (Tg) is the most sensitive biomarker for recurrence of differentiated thyroid cancer (DTC). We have assessed the changing pattern of stimulated Tg (sTg) and the clinical course of patients with no structural evidence of disease (NSED), based on imaging studies such as neck ultrasonography (US), fluorodeoxyglucose positron emission tomography, and/or chest computed tomogram (CT). We sought to determine if, in patients with DTC who had been treated with bilateral thyroidectomy and remnant ablation with radioactive iodine, sTg 1 year (sTg1) after initial treatment and repeated sTg measurements, 1-2 years after sTg1, helped predict the long-term outcome with respect to structural recurrence and biochemical remission (BR), which is defined as sTg <1 ng/mL. METHODS: We retrospectively assessed the records of patients with DTC who had been treated with bilateral thyroidectomy and remnant ablation with radioactive iodine between 1995 and 2004. The study included 186 patients who had NSED with sTg1 ≥2 ng/mL and subsequent sTg measurements (sTg2) without additional treatment. Patients were classified into three groups based on their sTg1 measurements: Group A, 2-4.9 ng/mL; Group B, 5-19.9 ng/mL; and Group C, ≥20 ng/mL. Patients were also classified into two groups based on whether sTg2, 1-2 years after sTg1, had decreased by ≥50% (Group 1) or had either decreased by <50% or increased (Group 2). sTg was measured every 1-2 years until structural recurrence or BR. RESULTS: Patients remaining in NSED showed a decrease in serial sTg. Of patients in Groups A, B, and C, 41%, 17%, and 1%, respectively, achieved BR, and there was a significant difference in the BR rate between Groups 1 and 2 (p<0.001). In patients with structural recurrence, serial sTg generally did not decrease from sTg1. There was a significant difference in the recurrence rate among Groups A, B, and C (p=0.005) and between Groups 1 and 2 (p<0.001). CONCLUSIONS: We found that 41% of patients with sTg1 in the range 2-5 ng/mL achieved BR, and that sTg1 and percent change of subsequent sTg were predictive of BR. Repeated sTg measurements are useful for predicting patient prognosis in patients with DTC.
BACKGROUND: Serum thyroglobulin (Tg) is the most sensitive biomarker for recurrence of differentiated thyroid cancer (DTC). We have assessed the changing pattern of stimulated Tg (sTg) and the clinical course of patients with no structural evidence of disease (NSED), based on imaging studies such as neck ultrasonography (US), fluorodeoxyglucose positron emission tomography, and/or chest computed tomogram (CT). We sought to determine if, in patients with DTC who had been treated with bilateral thyroidectomy and remnant ablation with radioactive iodine, sTg 1 year (sTg1) after initial treatment and repeated sTg measurements, 1-2 years after sTg1, helped predict the long-term outcome with respect to structural recurrence and biochemical remission (BR), which is defined as sTg <1 ng/mL. METHODS: We retrospectively assessed the records of patients with DTC who had been treated with bilateral thyroidectomy and remnant ablation with radioactive iodine between 1995 and 2004. The study included 186 patients who had NSED with sTg1 ≥2 ng/mL and subsequent sTg measurements (sTg2) without additional treatment. Patients were classified into three groups based on their sTg1 measurements: Group A, 2-4.9 ng/mL; Group B, 5-19.9 ng/mL; and Group C, ≥20 ng/mL. Patients were also classified into two groups based on whether sTg2, 1-2 years after sTg1, had decreased by ≥50% (Group 1) or had either decreased by <50% or increased (Group 2). sTg was measured every 1-2 years until structural recurrence or BR. RESULTS:Patients remaining in NSED showed a decrease in serial sTg. Of patients in Groups A, B, and C, 41%, 17%, and 1%, respectively, achieved BR, and there was a significant difference in the BR rate between Groups 1 and 2 (p<0.001). In patients with structural recurrence, serial sTg generally did not decrease from sTg1. There was a significant difference in the recurrence rate among Groups A, B, and C (p=0.005) and between Groups 1 and 2 (p<0.001). CONCLUSIONS: We found that 41% of patients with sTg1 in the range 2-5 ng/mL achieved BR, and that sTg1 and percent change of subsequent sTg were predictive of BR. Repeated sTg measurements are useful for predicting patient prognosis in patients with DTC.
Authors: E L Mazzaferri; R J Robbins; C A Spencer; L E Braverman; F Pacini; L Wartofsky; B R Haugen; S I Sherman; D S Cooper; G D Braunstein; S Lee; T F Davies; B M Arafah; P W Ladenson; A Pinchera Journal: J Clin Endocrinol Metab Date: 2003-04 Impact factor: 5.958
Authors: E Baudin; C Do Cao; A F Cailleux; S Leboulleux; J P Travagli; M Schlumberger Journal: J Clin Endocrinol Metab Date: 2003-03 Impact factor: 5.958
Authors: F Pacini; E Molinaro; F Lippi; M G Castagna; L Agate; C Ceccarelli; D Taddei; R Elisei; M Capezzone; A Pinchera Journal: J Clin Endocrinol Metab Date: 2001-12 Impact factor: 5.958
Authors: B R Haugen; F Pacini; C Reiners; M Schlumberger; P W Ladenson; S I Sherman; D S Cooper; K E Graham; L E Braverman; M C Skarulis; T F Davies; L J DeGroot; E L Mazzaferri; G H Daniels; D S Ross; M Luster; M H Samuels; D V Becker; H R Maxon; R R Cavalieri; C A Spencer; K McEllin; B D Weintraub; E C Ridgway Journal: J Clin Endocrinol Metab Date: 1999-11 Impact factor: 5.958
Authors: F Pacini; L Agate; R Elisei; M Capezzone; C Ceccarelli; F Lippi; E Molinaro; A Pinchera Journal: J Clin Endocrinol Metab Date: 2001-09 Impact factor: 5.958
Authors: M G Castagna; H P Tala Jury; C Cipri; V Belardini; C Fioravanti; L Pasqui; F Sestini; A Theodoropoulou; F Pacini Journal: J Endocrinol Invest Date: 2011-03-07 Impact factor: 4.256
Authors: A Iervasi; G Iervasi; M Ferdeghini; C Solimeo; A Bottoni; L Rossi; C Colato; G C Zucchelli Journal: Clin Endocrinol (Oxf) Date: 2007-06-06 Impact factor: 3.478
Authors: C F A Eustatia-Rutten; J W A Smit; J A Romijn; E P M van der Kleij-Corssmit; A M Pereira; M P Stokkel; J Kievit Journal: Clin Endocrinol (Oxf) Date: 2004-07 Impact factor: 3.478
Authors: Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky Journal: Thyroid Date: 2016-01 Impact factor: 6.568
Authors: Eun Kyung Jang; Won Gu Kim; Hyemi Kwon; Yun Mi Choi; Min Ji Jeon; Tae Yong Kim; Young Kee Shong; Won Bae Kim; Eui Young Kim Journal: Eur Thyroid J Date: 2015-08-20